S-1: Cidara Therapeutics Files for Resale of 7.04 Million Shares Following Private Placement
Sentiment:
S-1 Filing
Cidara Therapeutics is registering the resale of 7,041,309 shares of its common stock by selling stockholders after a recent private placement.
Capital raiseThe company sold and issued to the selling stockholders in the Private Placement (i) an aggregate of 3,892,274 shares of Common Stock, at a purchase price of $14.912 per share, and (ii) in lieu of shares of Common Stock to certain selling stockholders, Pre-Funded Warrants to purchase up to an aggregate of 3,149,035 shares of Common Stock at a purchase price of $14.9119 per Pre-Funded Warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per Warrant Share).The company received aggregate gross proceeds from the Private Placement of approximately $105.0 million, before deducting estimated offering expenses payable by us.
Summary
- Cidara Therapeutics has filed a registration statement for the resale of up to 7,041,309 shares of its common stock.
- The shares consist of 3,892,274 issued shares and 3,149,035 shares issuable upon exercise of pre-funded warrants.
- These shares were issued in a private placement that closed on November 26, 2024, raising approximately $105.0 million before expenses.
- The company will not receive any proceeds from the resale of these shares by the selling stockholders.
- The filing includes recast financial statements for 2022 and 2023, as well as for the nine-month periods ending September 30, 2024 and 2023, due to the sale of rezafungin.
- The company completed a 1-for-20 reverse stock split on April 23, 2024.
- The company's lead clinical asset is CD388, intended for influenza prophylaxis, and its lead oncology DFC is CBO421, targeting CD73 for solid tumors.
- The company initiated the CD388 Phase 2b NAVIGATE study in September 2024 and expects topline data in the third quarter of 2025.
Sentiment
Score: 6
Explanation: The document presents a mixed sentiment. While the company has secured funding and is advancing its clinical programs, it also faces ongoing losses and risks inherent in the biotechnology industry.
Positives
- The company reacquired all rights to develop and commercialize CD388 by executing the Janssen License Agreement in April 2024.
- The company initiated the CD388 Phase 2b NAVIGATE study in September 2024 and expects topline data in the third quarter of 2025.
- The company divested rezafungin in April 2024 to focus on its Cloudbreak platform, estimating $128.0 million in cost savings over the patent life of rezafungin.
- The company received aggregate gross proceeds of approximately $105.0 million from the Private Placement.
Negatives
- The company has a limited operating history and has experienced net losses and negative cash flows from operating activities since its inception.
- The company expects to continue to incur net losses into the foreseeable future.
- The company will not receive any proceeds from the sale of shares of Common Stock covered by this prospectus.
Risks
- Investing in the company's common stock involves a high degree of risk.
- The company's business, financial condition, results of operations or prospects could be materially adversely affected by various risks.
- The trading price of the company's common stock could decline due to any of these risks, and investors may lose all or part of their investment.
- The company's ability to execute its current business plan depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements.
- The company may be impacted by broader macroeconomic conditions, including global pandemics, high inflation, bank failures, labor shortages, supply chain disruptions, recession risks, the recent presidential election in the U.S. and potential disruptions from the ongoing Russia-Ukraine conflict and related sanctions and the active conflicts in the Middle East.
Future Outlook
The company expects to continue to incur net losses into the foreseeable future and is dependent on additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements.
Industry Context
The company is operating in the biotechnology industry, which is subject to various trends, events, and uncertainties, including macroeconomic conditions, global pandemics, and geopolitical events. The stock market, particularly for pharmaceutical and biotechnology companies, has experienced significant volatility.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares.
- Employees may be affected by the company's cost-cutting measures, including workforce reductions.
- Customers and patients may benefit from the development of new therapies.
- Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.
Next Steps
- The company will continue to develop CD388 as a universal preventative against seasonal and pandemic influenza A and B, beginning with the CD388 Phase 2b NAVIGATE study.
- The company expects topline data from the CD388 Phase 2b NAVIGATE study in the third quarter of 2025.
- The company will continue business development discussions for its oncology DFC programs, including CBO421.
Key Dates
| Date | Description |
|---|---|
| 2012-12-01 | Cidara Therapeutics incorporated as K2 Therapeutics, Inc. |
| 2014-07-01 | Company name changed to Cidara Therapeutics, Inc. |
| 2015-03-01 | Board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan |
| 2016-03-01 | Cidara Therapeutics UK Limited formed. |
| 2016-10-03 | Company entered into a loan and security agreement with Pacific Western Bank. |
| 2018-05-31 | Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock. |
| 2018-10-01 | Cidara Therapeutics (Ireland) Limited formed. |
| 2019-09-03 | Company entered into the Mundipharma Collaboration Agreement. |
| 2020-08-12 | 52,241 shares of Series X Convertible Preferred Stock were converted to common stock. |
| 2020-11-30 | Company approved and adopted the 2020 Inducement Incentive Plan. |
| 2021-03-31 | Company entered into the Janssen Collaboration Agreement. |
| 2022-07-26 | Company entered into a License Agreement with Melinta Therapeutics, LLC. |
| 2023-03-07 | Company issued shares of common stock and Series X Convertible Preferred Stock upon the closing of concurrent but separate public offerings. |
| 2024-04-04 | Stockholders approved a proposal to effect a reverse stock split and a reduction in the number of authorized shares of common stock. |
| 2024-04-23 | Company effected a 1-for-20 reverse stock split. |
| 2024-04-23 | Company entered into the Janssen License Agreement. |
| 2024-04-23 | Company entered into the Series A Securities Purchase Agreement. |
| 2024-04-24 | Company entered into the Napp Purchase Agreement and completed all conditions of the sale. |
| 2024-07-18 | Stockholders approved the adoption of a new 2024 Equity Incentive Plan. |
| 2024-09-20 | Company initiated the CD388 Phase 2b NAVIGATE study. |
| 2024-11-20 | Company entered into the Purchase Agreement with the selling stockholders. |
| 2024-11-26 | Private Placement closed. |
Keywords
resale, common stock, private placement, CD388, rezafungin, Cloudbreak, Cidara Therapeutics, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.